Support teaching, research, and patient care.
Dr. Wu is a board-certified cardiologist. He is the director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology at Stanford University School of Medicine. His clinical interests include adult congenital heart disease and cardiovascular imaging. He strives to help each patient achieve the best possible heart health and quality of life.The American Heart Association appointed Dr. Wu as its president for fiscal year 2023-2024.To advance heart care, Dr. Wu conducts extensive research, focusing on clinical genomics, stem cells, and drug development. The goals of his research are to enhance our understanding of cardiovascular diseases, accelerate the discovery of new drug treatments, and ensure that every cardiovascular patient will benefit from the best of personalized precision medicine being developed at Stanford Medicine.Dr. Wu has published more than 600 manuscripts with H-index of 129. He is recognized as top 0.1% of highly cited researchers in Web of Science for past 6 years (2018, 2019, 2020, 2021, 2022, 2023) in the fields of cardiovascular medicine, stem cells, genomics, and precision medicine. His work has appeared in peer-reviewed journals including Nature, Cell, Science, Nature Medicine, Nature Methods, Science Translational Medicine, Cell Stem Cell, PNAS, Circulation, Journal of the American College of Cardiology, European Heart Journal, and many more. Dr. Wu also educates the heart specialists of the future. More than 50 of his trainees are now principal investigators of clinical or research studies in major academic centers both in the US and internationally.He has earned numerous honors, including the Distinguished Scientist Award from the American Heart Association, NIH Director’s New Innovator Award, and NIH Director's Transformative Research Award. He also received the Presidential Early Career Award for Scientists and Engineers (PECASE) from the White House Office of Technology.Dr. Wu is an elected member of the National Academy of Medicine (NAM), National Academy of Inventors (NAI), American Association for the Advancement of Science (AAAS), American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), Academia Sinica (Taiwan), Association of University Cardiologists (AUC), and American Institute for Medical and Biological Engineering (AIMBE). He is an honorary lifetime member of the Society of Toxicology (SOT). He also serves on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee. For more information, please visit his lab website: https://med.stanford.edu/wulab.html
His lab works on cardiovascular genomics and induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision medicine for patients.
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
This study will assess the safety and efficacy of intracoronary artery administered
autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial
infarction (STEMI). This will be assessed by evaluating and comparing the autologous stem
cell treatment group to the control group in terms of the occurrence of AE's, SAE's and Major
Adverse Cardiac Events (MACE), by the change in myocardial perfusion (RTSS) measured
quantitatively by gated single photon emission computed tomography myocardial perfusion
imaging (gated SPECT MPI), and other secondary endpoints such as LVEF measured by cardiac MRI
in addition to other endpoints.
View full details